Does a kampo medicine containing schisandra fruit affect pharmacokinetics of nifedipine like grapefruit juice?

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 10, 2006, Pages 2065-2069

  Makino, Toshiaki ^a   Mizuno, Fumika ^a   Mizukami, Hajime ^a  

^a NAGOYA CITY UNIVERSITY   (Japan)

Author keywords

Cytochrome P450; Nifedipine; Pharmacokinetic interaction; Schisandra chinensis; Shoseiryuto

Indexed keywords

HERBACEOUS AGENT; KAMPO; NIFEDIPINE; PLANT EXTRACT;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GRAPEFRUIT JUICE; IN VITRO STUDY; NONHUMAN; RAT; SCHISANDRACEAE;

ANIMALS; BEVERAGES; CITRUS PARADISI; CYTOCHROME P-450 CYP3A; HERB-DRUG INTERACTIONS; MALE; MEDICINE, KAMPO; NIFEDIPINE; RATS; SCHISANDRA;

EID: 33749430489     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.2065     Document Type: Article

References (27)

1. Cooper E. L., Evid. Based Complement. Alternat. Med., 1, 1-4 (2004).
2. Terasawa K., Evid. Based Complement. Alternat. Med., 1, 119-123 (2004).
3. Fugh-Berman A., Ernst E., Bri. J. Clin. Pharmacol., 52, 587-595 (2001).
4. Mills E., Wu P., Johnston B. C., Gallicano K., Clarke M., Guyatt G., Ther. Drug Monit., 27, 549-557 (2005).
5. Chavez M. L., Jordan M. A., Chavez P. I., Life Sci., 78, 2146-2157 (2006).
6. Bailey D. G., Spence J. D., Munoz C., Arnold J. M., Lancet, 337, 268-269 (1991).
7. Niggemann B., Gruber C., Allergy, 58, 707-716 (2003).
8. Ernst E., Pharmacoepidemiol. Drug Saf., 13, 767-771 (2004).
9. Iwata H., Tezuka Y., Kadota S., Hiratsuka A., Watabe T., J. Trad. Med., 21, 281-286 (2004).
10. Iwata H., Tezuka Y., Usia T., Kadota S., Hiratsuka A., Watabe T., J. Trad. Med., 21, 42-50 (2004).
11. Ogikubo T., Hidaka M., Okumura M., Fujita L., Yamasaki K., Asai M., Iwakiri T., Sasaki H., Arimori K., Jpn. J. Phar. Health Care Sci., 32, 392-399 (2006).
12. Akao T., Kida H., Kanaoka M., Hattori M., Kobashi K., J. Pharm. Pharmacol., 50, 1155-1160 (1998).
13. Iwata H., Tezuka Y., Kadota S., Hiratsuka A., Watabe T., Drug Metab. Dispos., 32, 1351-1358 (2004).
14. Nagai H., Takeda H., Nishiyori T., Ochi T., Sawada M., Kato T., Inagaki N., Morita M., Komatsu Y., J. Trad. Med., 17, 49-58 (2000).
15. Murayama T., Yamaguchi N., Iwamoto K., Eizuru Y., Antivir. Chem. Chemother., 17, 11-16 (2006).
16. Kimura M., Hasegawa A., Nakamura H., Ohmori S., Ishii I., Kitada M., Jpn. J. Pharm. Health Care Sci., 28, 360-365 (2002).
17. Fuhr U., Drug Saf., 18, 251-272 (1998).
18. Mohri K., Uesawa Y., Pharm. Res., 18, 177-182 (2001).
19. Guo L. Q., Yamazoe Y., Acta Pharmacol. Sin., 25, 129-136 (2004).
20. Society of Japanese Pharmacopoeia, "Japanese Pharmacopoeia," 15th ed., Yakuji Nippo, Tokyo, 2006.
21. Health Labor and Welfare Ministry Japan, "Guidlines for Manufacturing Drugs 2001," Jiho, Tokyo, 2001.
22. Bradford M. M., Anal. Biochem., 72, 248-254 (1976).
23. Tabata K., Yamaoka K., Kaibara A., Suzuki S., Terakawa M., Hata T., Xenobio. Metabol. Dispos., 14, 286-293 (1999).
24. Yanai S., "4 Steps Excel Statistics," OMS Publishers, Tokorozawa, Japan, 2004.
25. Ducharme M., Warbasse L., Edwards D., Clin. Pharmacol. Ther., 57, 485-491 (1995).
26. Takara K., Ohnishi N., Horibe S., Yokoyama T., Drug Metab. Dispos., 31, 1235-1239 (2003).
27. Grundy J. S., Eliot L. A., Foster R. T., Biopharm. Drug Dispos., 18, 509-522 (1997).